

AP20 RECEIVED 24 JAN 2006

14. The insulin derivative of claim 1, wherein said blood component is a blood protein.
15. The insulin derivative of claim 14, wherein said blood protein is serum albumin.
16. An insulin conjugate comprising an insulin derivative according to any one of claims 1 to 15 and a blood component, wherein the reactive group and the blood component are conjugated through a covalent bond formed between said reactive group and said blood component.
17. The insulin conjugate of claim 16, wherein the blood component is a blood protein.
18. The insulin conjugate of claim 17, wherein the blood protein is serum albumin.
19. The insulin conjugate of claim 16, wherein said conjugate was formed *ex vivo*.
20. The insulin conjugate of claim 19, wherein said blood component is recombinant albumin.
21. A pharmaceutical composition comprising the insulin derivative of any one of claims 1 to 15 in association with a pharmaceutically acceptable carrier.
22. A pharmaceutical composition comprising the insulin conjugate of any one of claims 16 to 20 in association with a pharmaceutically acceptable carrier.
23. A method for treating a glycaemic-related disease or disorder in a subject suffering from said glycaemic-related disease or disorder, comprising administering the insulin derivative of any one of claims 1 to 15 to said subject.

24. The method according to claim 23, wherein said glycaemic-related disease is selected from the group consisting of diabetes of type I, diabetes of type II, gestational diabetes, cystic fibrosis, polycystic ovary syndrome and pancreatitis.

25. The method according to claim 23, wherein the glycaemic-related disease is selected from the group consisting of diabetes of type I and diabetes of type II.

26. A method for treating a glycaemic-related disease or disorder, comprising the administration of the insulin conjugate of any one of claims 16 to 20.

27. The method according to claim 26, wherein said glycaemic-related disease is selected from the group consisting of diabetes of type I, diabetes of type II, gestational diabetes, cystic fibrosis, polycystic ovary syndrome and pancreatitis.

28. The method according to claim 26, wherein the glycaemic-related disease is selected from the group consisting of diabetes of type I and diabetes of type II.

29. A method for treating a glycaemic-related disease or disorder, comprising the administration of the pharmaceutical composition of any one of claims 21 and 22.

30. The method according to claim 29, wherein said glycaemic-related disease is selected from the group consisting of diabetes of type I, diabetes of type II, gestational diabetes, cystic fibrosis, polycystic ovary syndrome and pancreatitis.

31. The method according to claim 29, wherein the glycaemic-related disease is selected from the group consisting of diabetes of type I and diabetes of type II.

32. Use of the derivative of any one of claims 1 to 15, for the preparation of a medicament for the treatment of a glycaemic-related disease or disorder.

33. The use as claimed in claim 32, wherein said glycaemic-related disease is selected from the group consisting of diabetes of type I, diabetes of type II, gestational diabetes, cystic fibrosis, polycystic ovary syndrome and pancreatitis.

34. The use as claimed in claim 32, wherein the glycaemic-related disease is selected from the group consisting of diabetes of type I and diabetes of type II.

35. Use of the conjugate of any one of claims 16 to 20, for the preparation of a medicament for the treatment of a glycaemic-related disease or disorder.

36. The use as claimed in claim 35, wherein said glycaemic-related disease is selected from the group consisting of diabetes of type I, diabetes of type II, gestational diabetes, cystic fibrosis, polycystic ovary syndrome and pancreatitis.

37. The use as claimed in claim 36, wherein the glycaemic-related disease is selected from the group consisting of diabetes of type I and diabetes of type II.